Brokers Issue Forecasts for Immunome FY2025 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Immunome in a research note issued on Thursday, February 12th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($2.37) for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Immunome’s Q4 2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.78) EPS, FY2027 earnings at ($2.20) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at $0.63 EPS and FY2030 earnings at $1.28 EPS.

Several other brokerages have also commented on IMNM. Stephens upped their price objective on shares of Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a report on Monday, November 17th. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research note on Thursday, January 15th. Leerink Partners set a $40.00 price objective on shares of Immunome in a report on Monday, December 15th. Lake Street Capital lifted their price objective on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Finally, Guggenheim upped their target price on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Immunome presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.75.

Immunome Stock Down 1.2%

Shares of IMNM stock opened at $22.16 on Monday. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -7.51 and a beta of 2.32. The stock has a fifty day moving average of $22.48 and a 200 day moving average of $16.55. Immunome has a 52 week low of $5.15 and a 52 week high of $27.65.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after buying an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA lifted its stake in Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after acquiring an additional 1,667,432 shares during the period. State Street Corp lifted its stake in Immunome by 37.9% during the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after acquiring an additional 1,064,027 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after acquiring an additional 2,823,144 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Immunome by 24.6% in the fourth quarter. Geode Capital Management LLC now owns 2,361,381 shares of the company’s stock worth $50,731,000 after acquiring an additional 466,806 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Insider Buying and Selling at Immunome

In related news, insider Philip Tsai purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the purchase, the insider directly owned 43,300 shares of the company’s stock, valued at approximately $887,217. This represents a 30.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Isaac Barchas sold 383,200 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total value of $8,330,768.00. Following the transaction, the director directly owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. This trade represents a 15.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders acquired 68,518 shares of company stock valued at $1,453,958. Corporate insiders own 7.69% of the company’s stock.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Wedbush published a buy recommendation on Immunome, adding a second institutional endorsement that could attract fresh demand and lend support to the stock’s valuation. Immunome (IMNM) Receives a Buy from Wedbush
• Positive Sentiment: HC Wainwright reiterated a Buy on IMNM with a $40 price target and a long-term profit pathway (projects FY2029 and FY2030 profitability). That $40 target is materially above the current market price and is a clear positive catalyst for investors focused on upside from analyst targets. HC Wainwright coverage (MarketBeat summary)
• Neutral Sentiment: HC Wainwright published a detailed multi-year EPS model (quarterly and annual estimates through FY2030) that provides a roadmap for expected cash burn, R&D timing and when profitability might emerge — useful for modeling but not an immediate catalyst on its own. HC Wainwright coverage (MarketBeat summary)
• Negative Sentiment: HC Wainwright’s near‑term forecasts show substantial losses (e.g., FY2026 EPS of -$2.78 vs. a current consensus of -$2.21), signaling heavier near‑term dilution/ cash burn than consensus — a headwind for the share price until clinical or commercial proofs reduce execution risk. HC Wainwright coverage (MarketBeat summary)
• Negative Sentiment: Price action and volume are weak today (shares down; volume below the stock’s average), with the 50‑day moving average just above current levels — technicals point to short‑term weakness even as longer‑term averages remain supportive.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.